JP2004525957A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525957A5
JP2004525957A5 JP2002580924A JP2002580924A JP2004525957A5 JP 2004525957 A5 JP2004525957 A5 JP 2004525957A5 JP 2002580924 A JP2002580924 A JP 2002580924A JP 2002580924 A JP2002580924 A JP 2002580924A JP 2004525957 A5 JP2004525957 A5 JP 2004525957A5
Authority
JP
Japan
Prior art keywords
sodium
product
pharmaceutical composition
sodium caprate
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002580924A
Other languages
English (en)
Japanese (ja)
Other versions
JP5026655B2 (ja
JP2004525957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/000535 external-priority patent/WO2002083120A2/en
Publication of JP2004525957A publication Critical patent/JP2004525957A/ja
Publication of JP2004525957A5 publication Critical patent/JP2004525957A5/ja
Application granted granted Critical
Publication of JP5026655B2 publication Critical patent/JP5026655B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002580924A 2001-04-18 2002-04-18 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体 Expired - Lifetime JP5026655B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28445801P 2001-04-18 2001-04-18
US60/284,458 2001-04-18
PCT/CA2002/000535 WO2002083120A2 (en) 2001-04-18 2002-04-18 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009272679A Division JP5657879B2 (ja) 2001-04-18 2009-11-30 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体

Publications (3)

Publication Number Publication Date
JP2004525957A JP2004525957A (ja) 2004-08-26
JP2004525957A5 true JP2004525957A5 (enExample) 2009-08-20
JP5026655B2 JP5026655B2 (ja) 2012-09-12

Family

ID=23090294

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002580924A Expired - Lifetime JP5026655B2 (ja) 2001-04-18 2002-04-18 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
JP2009272679A Expired - Lifetime JP5657879B2 (ja) 2001-04-18 2009-11-30 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
JP2014165557A Expired - Lifetime JP6420089B2 (ja) 2001-04-18 2014-08-15 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2009272679A Expired - Lifetime JP5657879B2 (ja) 2001-04-18 2009-11-30 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
JP2014165557A Expired - Lifetime JP6420089B2 (ja) 2001-04-18 2014-08-15 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体

Country Status (30)

Country Link
US (2) US7745488B2 (enExample)
EP (2) EP1385498B1 (enExample)
JP (3) JP5026655B2 (enExample)
KR (1) KR20030096323A (enExample)
CN (1) CN1633286A (enExample)
AP (1) AP1740A (enExample)
AU (2) AU2002308456B2 (enExample)
BG (1) BG66418B1 (enExample)
BR (1) BR0208984A (enExample)
CA (2) CA2444463C (enExample)
CY (1) CY1107081T1 (enExample)
CZ (1) CZ305273B6 (enExample)
DE (1) DE60223670T2 (enExample)
DK (2) DK1385498T3 (enExample)
EA (1) EA007322B1 (enExample)
EE (1) EE200300510A (enExample)
ES (2) ES2295397T3 (enExample)
HU (1) HUP0303817A3 (enExample)
IL (3) IL158322A0 (enExample)
MX (1) MXPA03009436A (enExample)
NO (1) NO335105B1 (enExample)
NZ (2) NZ541140A (enExample)
OA (1) OA12506A (enExample)
PL (2) PL223348B1 (enExample)
PT (2) PT1900364E (enExample)
SI (1) SI1385498T1 (enExample)
SK (1) SK12772003A3 (enExample)
TN (1) TNSN03089A1 (enExample)
WO (1) WO2002083120A2 (enExample)
ZA (1) ZA200307778B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444463C (en) 2001-04-18 2012-03-20 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
DE04708802T1 (de) * 2003-02-07 2006-06-22 Prometic Biosciences Inc., Montreal Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
DE602004006137T3 (de) 2003-07-25 2012-01-19 Prometic Biosciences Inc. Herstellung von metallsalzen von fettsäuren mit mittlerer kettenlänge
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
CA2578993A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
NZ554176A (en) 2004-10-01 2010-04-30 Prometic Biosciences Inc Medium-chain length fatty alcohols as stimulators of hematopoiesis
US8071580B2 (en) * 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
EP1858912B1 (en) * 2005-02-28 2012-04-11 Alphabeta AB Compounds for reducing aggregation of amyloid beta-peptide
CA2687446A1 (en) * 2006-05-17 2007-11-29 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
PT2299998T (pt) 2007-11-02 2018-04-02 Prometic Pharma Smt Ltd Acidos gordos e glicerídeos de cadeia média como agentes nefroprotetores
EP2231166B1 (en) * 2007-12-19 2013-03-20 ProMetic BioSciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
EP2165713B1 (en) * 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
JP2013500966A (ja) 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
RU2646823C2 (ru) 2013-08-19 2018-03-07 Энзикем Лайфсайенсиз Корпорейшн Композиция для предотвращения или лечения ревматоидного артрита, содержащая в качестве активного ингредиента моноацетилдиглицерид
KR20180015297A (ko) * 2014-05-15 2018-02-12 주식회사 엔지켐생명과학 백혈구 감소증 및 혈소판 감소증에 대한 치료 방법
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
US9808438B2 (en) 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
TWI749016B (zh) 2016-06-08 2021-12-11 董宇紅 具有奇數碳的脂類化合物及其作為醫藥組合物或者營養補充劑的用途
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN107382710B (zh) * 2017-08-19 2020-11-06 中国铁道科学研究院集团有限公司铁道建筑研究所 一种接枝抗氧剂分子的多元醇
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
BR112020006841A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido
AU2018345812A1 (en) * 2017-10-05 2020-05-14 Spoke Sciences, Inc. Herbal compositions with improved bioavailability
KR102054401B1 (ko) * 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
CA3112073A1 (en) 2018-10-11 2020-04-16 Basf As Aromatic compounds and pharmaceutical uses thereof
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
WO2021085144A1 (ja) * 2019-10-31 2021-05-06 日本ゼオン株式会社 電気化学素子用機能層およびその製造方法、電気化学素子用機能層付きセパレータおよびその製造方法、並びに電気化学素子およびその製造方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
WO2023067501A1 (en) * 2021-10-18 2023-04-27 Enzychem Lifesciences Corporation Compositions and methods for treating mucositis
US20250270471A1 (en) * 2022-04-21 2025-08-28 Merck Sharp & Dohme Llc Process for preparing agglomerated crystalline medium-chain fatty acid sodium salts

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4703062A (en) * 1984-01-16 1987-10-27 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH02134326A (ja) * 1988-11-14 1990-05-23 Snow Brand Milk Prod Co Ltd 高度侵襲用経腸栄養剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
CA2081104A1 (en) * 1991-02-22 1992-08-23 Glenn Pierce Use of gm-csf and g-csf to promote accelerated wound healing
JP3132085B2 (ja) * 1991-09-06 2001-02-05 ウェルファイド株式会社 脂肪乳剤
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
AU7082694A (en) * 1994-05-10 1995-11-29 Kitasato Institute, The Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
ATE230262T1 (de) * 1995-11-28 2003-01-15 Braun Melsungen Ag Lipidemulsionen mit optimierter hydrolyse sowie deren verwendung
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) * 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6017531A (en) * 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
JP2001514209A (ja) 1997-09-04 2001-09-11 バイオゾーン ラボラトリーズ，インコーポレイテッド 経口リポソーム送達系
WO1999025312A1 (en) * 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
EP1061932B1 (en) * 1997-11-20 2006-01-25 Gil Ja Jhon Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
KR20010041696A (ko) 1998-03-11 2001-05-25 그레랑 파마수티컬 가부시키가이샤 발포성 장용(腸溶) 제제
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2001022937A1 (en) * 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ATE341331T1 (de) * 2000-06-14 2006-10-15 William Leslie Porter Lipide zur änderung des abwehrsystems
CN100348183C (zh) * 2000-06-20 2007-11-14 营养科学公司 可用作抗微生物剂的中链脂肪酸
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
CA2444463C (en) 2001-04-18 2012-03-20 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
DE04708802T1 (de) 2003-02-07 2006-06-22 Prometic Biosciences Inc., Montreal Fettsäuren mittlerer kettenlänge, glyceride und analoga als stimulatoren der erythropoiese
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
DE602004006137T3 (de) 2003-07-25 2012-01-19 Prometic Biosciences Inc. Herstellung von metallsalzen von fettsäuren mit mittlerer kettenlänge
CA2578993A1 (en) * 2004-09-03 2006-03-09 Prometic Biosciences Inc. Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Similar Documents

Publication Publication Date Title
JP2004525957A5 (enExample)
Sonis Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity
Tanikawa et al. Effects of recombinant human granulocyte colony-stimulating factor on the hematologic recovery and survival of irradiated mice
EP2105136A3 (en) Pharmaceutical compositions for treating cancer
CA2444463A1 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
WO2005048950A3 (en) Tumor and infectious disease therapeutic compositions
Antunes et al. Oral and maxillofacial myiasis: a case series and literature review
EP2319531A3 (en) Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
CA2520515A1 (en) S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DE69832902T2 (de) Oromukosal-zytokin-zusammensetzungen und ihre verwendung
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
Donnelly et al. Can anything be done about oral mucositis?
RU2332227C1 (ru) Способ комплексной терапии больных с плоскоклеточным раком слизистой полости рта
Tilg et al. Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression?
DE60130775D1 (de) Stimulierung der neutrophilfunktion zur behandlung von entzündlichen darmerkrankungen
JP2003528139A5 (enExample)
SE0400942D0 (sv) Composition and method
Davletshina et al. Prospective methods of vitiligo treatment (literature review)
Nikolaou et al. Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-α. A phase II study
Ullmann et al. of Inf ectious Diseases
Zagożdżon et al. The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production
Bonello et al. Non-neoplastic proliferative oral lesions
Leonard et al. Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma
RU2020127722A (ru) Естественные клетки-киллеры, резистентные к трансформирующему ростовому фактору бета